세계의 자가면역성 용혈성 빈혈 치료제 시장은 2030년까지 8억 7,370만 달러에 달할 전망
2023년에 5억 3,560만 달러로 추정되는 세계의 자가면역성 용혈성 빈혈 치료제 시장은 2030년에는 8억 7,370만 달러에 달하며, 분석 기간인 2023-2030년의 CAGR은 7.2%로 성장할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 부신피질 스테로이드는 CAGR 8.0%를 기록하며, 분석 기간 종료시에는 5억 910만 달러에 달할 것으로 예측됩니다. 모노클로널 항체 분야의 성장률은 분석 기간 중 CAGR 6.9%로 추정됩니다.
미국 시장은 1억 4,590만 달러로 추정, 중국은 CAGR 11.7%로 성장할 것으로 예측
미국의 자가면역성 용혈성 빈혈 치료제 시장은 2023년에 1억 4,590만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2023-2030년의 분석 기간에 CAGR 11.7%로 추이하며, 2030년에는 1억 9,470만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.1%와 7.2%로 예측됩니다. 유럽에서는 독일이 CAGR 4.6%로 성장할 것으로 예측됩니다.
세계의 자가면역성 용혈성 빈혈 치료제 시장 - 주요 촉진요인과 동향 정리
자가면역성 용혈성 빈혈(AIHA) 치료제는 면역계가 체내 적혈구를 잘못 공격하고 파괴하는 희귀질환인 AIHA의 증상을 관리하고 완화하는 것을 목표로 하는 일련의 치료법을 포함합니다. 이로 인해 피로, 창백한 얼굴, 숨가쁨, 황달을 특징으로 하는 용혈성 빈혈이 발생합니다. 치료에는 부신피질 스테로이드, 면역 억제제, 단일 클론 항체, 수혈과 같은 지지 요법이 포함됩니다. 이러한 치료제의 주요 목적은 적혈구 파괴율을 낮추고, 면역 반응을 관리하고, 증상을 치료하여 환자의 삶의 질을 개선하는 것입니다.
최근 AIHA의 병태생리 및 면역 기전에 대한 이해가 깊어지면서 AIHA 치료제의 개발이 크게 진전되고 있습니다. 프레드니손과 같은 부신피질 스테로이드는 염증과 면역 활동을 억제하는 효과가 있으므로 종종 치료의 첫 번째 선택이 됩니다. 그러나 장기간 사용시 부작용이 발생할 수 있으며, 대체 요법의 필요성이 대두되고 있으며, B세포의 CD20을 표적으로 하는 단클론 항체인 리툭시맙과 같은 면역억제제는 스테로이드가 듣지 않는 난치성 환자에서 유망한 치료제로 떠오르고 있습니다. 또한 보체 억제제나 적혈구 파괴에 관여하는 경로를 특이적으로 표적하는 저분자 약물과 같은 새로운 치료법도 검토되고 있습니다. 이러한 기술 혁신은 치료의 폭을 넓히고 AIHA를 더 잘 관리할 수 있는 희망을 가져다주고 있습니다.
AIHA 치료제 시장의 성장은 표적 치료의 발전, 진단 인식의 향상, 자가면역질환의 유병률 증가 등 여러 요인에 의해 주도되고 있습니다. 바이오테크놀러지의 기술 발전으로 단클론 항체 및 신규 면역조절제 등 보다 효과적이고 특이적인 치료법 개발이 가능해져 환자들의 예후가 개선되고 있습니다. AIHA에 대한 인식의 향상과 진단 기술의 개선으로 AIHA를 조기에 정확하게 발견하여 적시에 개입하고 질병을 더 잘 관리할 수 있게 되었습니다. 또한 전 세계에서 자가면역질환의 유병률이 증가함에 따라 치료가 필요한 환자 수가 증가하고 있습니다. 제약사들은 이 분야의 미충족 의료 수요에 대한 인식이 높아짐에 따라 새로운 치료법을 시장에 출시하기 위해 연구개발에 투자하고 있습니다. 이러한 요인들은 AIHA 치료제 시장의 성장을 가속하고 환자와 의료진에게 새로운 희망을 가져다주고 있습니다.
조사 대상 기업의 예(총 56건)
Alkem Laboratories Limited
Alnylam Pharmaceuticals, Inc.
Alpine Immune Sciences
Amneal Pharmaceuticals Inc.
Annexon Biosciences
Apellis Pharmaceuticals Inc.
argenx SE
Incyte Corporation
Johnson & Johnson Services, Inc.
Lupin Pharmaceuticals, Inc.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Rigel Pharmaceuticals Inc.
Sanofi SA;
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장의 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSA
영문 목차
영문목차
Global Autoimmune Hemolytic Anemia Therapeutics Market to Reach US$873.7 Million by 2030
The global market for Autoimmune Hemolytic Anemia Therapeutics estimated at US$535.6 Million in the year 2023, is expected to reach US$873.7 Million by 2030, growing at a CAGR of 7.2% over the analysis period 2023-2030. Corticosteroids, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$509.1 Million by the end of the analysis period. Growth in the Monoclonal Antibodies segment is estimated at 6.9% CAGR over the analysis period.
The U.S. Market is Estimated at US$145.9 Million While China is Forecast to Grow at 11.7% CAGR
The Autoimmune Hemolytic Anemia Therapeutics market in the U.S. is estimated at US$145.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$194.7 Million by the year 2030 trailing a CAGR of 11.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.
Global Autoimmune Hemolytic Anemia Therapeutics Market - Key Drivers and Trends Summarized
Autoimmune Hemolytic Anemia (AIHA) therapeutics encompass a range of treatments aimed at managing and alleviating the symptoms of AIHA, a rare condition where the immune system mistakenly attacks and destroys the body's red blood cells. This leads to hemolytic anemia, characterized by fatigue, pallor, shortness of breath, and jaundice. The therapeutic landscape includes corticosteroids, immunosuppressive agents, monoclonal antibodies, and supportive treatments such as blood transfusions. The primary goal of these therapeutics is to reduce the rate of red blood cell destruction, manage the immune response, and address symptoms to improve patient quality of life.
In recent years, the development of AIHA therapeutics has seen significant advancements, driven by a deeper understanding of the disease’s pathophysiology and immune mechanisms. Corticosteroids like prednisone are often the first line of treatment due to their efficacy in reducing inflammation and immune activity. However, long-term use can result in adverse effects, prompting the need for alternative therapies. Immunosuppressive agents such as rituximab, a monoclonal antibody targeting CD20 on B-cells, have shown promise in refractory cases where steroids are insufficient. Additionally, novel therapies are being explored, including complement inhibitors and small molecule drugs that specifically target pathways involved in red blood cell destruction. These innovations are expanding the treatment arsenal and offering hope for better management of AIHA.
The growth in the AIHA therapeutics market is driven by several factors, including advancements in targeted therapies, increased diagnostic awareness, and a rising prevalence of autoimmune disorders. Technological progress in biotechnology has enabled the development of more effective and specific treatments, such as monoclonal antibodies and novel immunomodulatory drugs, which have improved patient outcomes. Increased awareness and improved diagnostic techniques are leading to earlier and more accurate detection of AIHA, facilitating timely intervention and better management of the disease. Additionally, the rising prevalence of autoimmune conditions globally is contributing to a larger patient population requiring treatment. Pharmaceutical companies are investing in research and development to bring new therapies to market, spurred by the growing recognition of unmet medical needs in this area. These factors collectively drive the expansion of the AIHA therapeutics market, offering new hope for patients and healthcare providers.
Select Competitors (Total 56 Featured) -
Alkem Laboratories Limited
Alnylam Pharmaceuticals, Inc.
Alpine Immune Sciences
Amneal Pharmaceuticals Inc.
Annexon Biosciences
Apellis Pharmaceuticals Inc.
argenx SE
Incyte Corporation
Johnson & Johnson Services, Inc.
Lupin Pharmaceuticals, Inc.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Rigel Pharmaceuticals Inc.
Sanofi SA;
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Autoimmune Hemolytic Anemia Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Autoimmune Hemolytic Anemia Drives Demand for Therapeutics
Advancements in Diagnostic Technologies Propel Growth in Anemia Therapeutics Market
Growing Awareness of Rare Diseases Spurs Demand for Specialized Treatments
Innovations in Monoclonal Antibody Therapies Generate Market Interest
Expansion of Biopharmaceutical Sector Drives Adoption of Novel Therapies
Advances in Immunotherapy Techniques Generate New Market Opportunities
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Autoimmune Hemolytic Anemia Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 14: USA Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 15: USA Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 16: USA 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
CANADA
TABLE 17: Canada Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 18: Canada Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 19: Canada 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
JAPAN
Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 20: Japan Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 21: Japan Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 22: Japan 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
CHINA
Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 23: China Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 24: China Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 25: China 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
EUROPE
Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 26: Europe Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 27: Europe Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 28: Europe 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 29: Europe Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 30: Europe Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 31: Europe 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
FRANCE
Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 32: France Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 33: France Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 34: France 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
GERMANY
Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 35: Germany Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 36: Germany Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: Germany 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
ITALY
TABLE 38: Italy Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: Italy Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: Italy 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
UNITED KINGDOM
Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 41: UK Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 42: UK Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: UK 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
SPAIN
TABLE 44: Spain Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: Spain Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: Spain 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
RUSSIA
TABLE 47: Russia Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 48: Russia Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: Russia 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: Rest of Europe Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: Rest of Europe 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 54: Asia-Pacific Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 55: Asia-Pacific 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: Asia-Pacific Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 58: Asia-Pacific 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
AUSTRALIA
Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 59: Australia Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 60: Australia Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 61: Australia 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
INDIA
Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 62: India Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: India Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 64: India 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 65: South Korea Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: South Korea Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 67: South Korea 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: Rest of Asia-Pacific Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
LATIN AMERICA
Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 71: Latin America Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 72: Latin America Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 73: Latin America 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 74: Latin America Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 75: Latin America Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 76: Latin America 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 77: Argentina Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 78: Argentina Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 79: Argentina 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
BRAZIL
TABLE 80: Brazil Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 81: Brazil Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 82: Brazil 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
MEXICO
TABLE 83: Mexico Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 84: Mexico Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 85: Mexico 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: Rest of Latin America Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 88: Rest of Latin America 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
MIDDLE EAST
Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 89: Middle East Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 90: Middle East Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 91: Middle East 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 92: Middle East Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: Middle East Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 94: Middle East 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
IRAN
TABLE 95: Iran Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 96: Iran Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 97: Iran 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
ISRAEL
TABLE 98: Israel Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 99: Israel Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 100: Israel 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 102: Saudi Arabia Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 103: Saudi Arabia 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 104: UAE Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 105: UAE Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 106: UAE 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 108: Rest of Middle East Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 109: Rest of Middle East 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
AFRICA
Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 110: Africa Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 111: Africa Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 112: Africa 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
